Latham & Watkins LLP represented Terns Pharmaceuticals in the offering and Davis Polk advised the underwriters involved.Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
